Latest Research on GLP-1 Medications. (Nov.2024)
Semaglutide, a GLP-1 medication, is the first weight loss medication approved to reduce the risk of cardiovascular death, heart attack and stroke in adults who have cardiovascular disease. GLP-1 also helps manage blood sugar in people with type 2 diabetes, and individuals that are overweight or obese. In a 5-year study, Semaglutide reduced major cardiovascular events by 20%.
Additionally, research from Harvard Medical School and Brigham and Women’s Hospital indicates that as the use of GLP-1 medications increase, there is a decline in bariatric surgeries (a collection of procedures that modify the digestive system to help people lose weight. e.i. lab band, gastric bypass etc.). The study (between 2022 and 2023) showed a 132% increase in GLP-1 prescriptions and a 25.6% decrease in bariatric surgeries.
Other studies report a decrease in hospitalizations and length of hospital stays of
patients on GLP-1 medications. Novo Nordisk (the maker of Wegovy) has also
published research indicating a decrease in osteoarthritis knee pain by 37% and
improvement of liver function by 37%.
With a growing market and ongoing studies, many additional benefits (beyond weight management) are being researched, including alcohol use disorders, gambling addictions, regulation of ovulation in women with PCOS, treatment of IBS and other GI disorders, and improvement of renal function in patients with chronic kidney disease.
Would you like to learn more about Begin to Trim's weight management program? Call today 978-455-6800.